Skip to main content
. 2017 Dec 8;2017(1):66–72. doi: 10.1182/asheducation-2017.1.66

Table 2.

Somatic mutations and current and future targeted therapies

Mutation Drug
Flt3 Crenolanib and quizartinib
IDH1 AG-120
IDH2 AG-221
UTX EZH2 inhibitor
Heterozygous TET2 5-azacytidine/vitamin C?
DNMT3A S-adenosylmethionine?
JAK2 Ruxolitinib
cKIT Axitinib and dasatinib
Del 5q Lenalidomide
Spliceosomal factor H3B-8800?
CSF3R Ruxolitinib

?, future potential.